These results contradict a preclinical investigation, in which everolimus inhibited tumor growth in relative insensitive (human colon and cervical) and sensitive (human melanoma and lung cancer) mTOR cancer models; tumor [18F]FDG uptake after 2 and 7 days of treatment was only reduced in sensitive cell lines. This evidence concerns the gene MTOR and cancer.